Colorectal Cancer and Microsatellite Instability
Nouscom S.r.l. focuses on locally advanced unresectable and metastatic colorectal cancer with microsatellite instability-high or mismatch repair deficient disease, reflecting a clear interest in immunologically distinct gastrointestinal malignancies.
- MSI-H colorectal cancer
- dMMR tumors
- Metastatic CRC
The clinical work centers on tumor types that are characterized by altered DNA repair biology and heightened relevance for immune-based oncology.
Cancer Immunotherapy
The sponsor’s research activity is directed toward immunotherapy combinations in solid tumors, with emphasis on a vaccination regimen evaluated alongside pembrolizumab in anti-tumor treatment settings.
- Therapeutic cancer vaccination
- Checkpoint inhibitor combinations
- Anti-tumor immune response
This area highlights interest in strengthening immune recognition of tumor-associated targets within advanced colorectal malignancy.
Genetic Vaccines
Nouscom S.r.l. is active in genetic vaccine development for microsatellite unstable solid tumors, with a therapeutic focus on precision-driven approaches that use tumor biology to guide immune activation.
- Genetic vaccine platforms
- Microsatellite unstable solid tumors
- Tumor-directed immunization
The research landscape suggests a strong emphasis on applying vaccine-based strategies to cancers with distinctive genomic instability.
